keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromosome Positive Chronic Granulocytic Leukemia.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 7,500 | |||
10 mg | 在庫あり | ¥ 12,500 | |||
25 mg | 在庫あり | ¥ 18,500 | |||
50 mg | 在庫あり | ¥ 25,000 | |||
100 mg | 在庫あり | ¥ 37,500 | |||
500 mg | 在庫あり | ¥ 75,500 |
説明 | Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromosome Positive Chronic Granulocytic Leukemia. |
ターゲット&IC50 | Csk:314 nmol/L, Abl kinase:2.4 nmol/L |
In vitro | Bosutinib hydrate(SKI-606)was a inhibitor of two Src-related kinases (i.e., Fgr and Lyn with IC50s of 0.174 and 0.850 nmol/L, respectively)[2]. |
In vivo | Administration of Bosutinib hydrate(SKI-606) at doses of 75 mg/kg twice daily or 150 mg/kg once daily can promote complete regression of human K562 xenografts for up to 40 days[2]. |
別名 | PF-5208763 hydrate, PF-05208763 hydrate, SKI-606 hydrate |
分子量 | 548.46 |
分子式 | C26H31Cl2N5O4 |
CAS No. | 918639-08-4 |
keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (145.86 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bosutinib hydrate 918639-08-4 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl Src PF-5208763 hydrate PF-05208763 hydrate SKI-606 hydrate Inhibitor inhibitor inhibit